1. Burke, M.; Pal, P.; Zhang, P.; Zhang, X.*; Zheng, G., A Concise Synthesis of (S)-δ-CEHC, a Metabolite of Vitamin E. ACS Omega. 2021, 6(6), 4355-4361. doi.org/10.1021/acsomega.0c05658

2. Xiao, Y.; Zhang, X.*, Recent advances in small molecular modulators targeting histone deacetylase 6. Future Drug Discov. 2020, 2, FDD53. doi.org/10.4155/fdd-2020-0023

3. Xiao, Y.; Wang, J., Zhao, L.; Chen, X.; Zheng, G.; Zhang, X.*; Liao, D.*, Discovery of histone deacetylase 3 (HDAC3)-specific PROTACs. Chem. Commun. 2020, 56, 9866-9869. doi.org/10.1039/D0CC03243C

4. He, Y.^#; Zhang, X.^#; Chang, J.^#; Kim, H.-n.^#; Zhang, P.; Wang, Y.; Khan, S.; Liu, X.; Zhang, X.; Lv, D.; Song, L.; Li, W.; Thummuri, D.; Yuan, Y.; Wiegand, J. S.; Ortiz, Y. T.; Budamagunta, V.; Elisseeff, J.; Campisi, J.; Almeida, M.; Zheng, G.; Zhou, D., Using proteolysis targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity. Nat. Commun. 2020, 11, 1996. doi.org/10.1038/s41467-020-15838-0

5. Zhang, X.; He, Y.; Zhang, P.; Budamagunta, V; Lv, D.; Thummuri, D.; Yang, Y.; Pei, J., Yuan, Y.; Zhou, D.; Zheng, G. Discovery of IAP-Recruiting BCL-XL PROTACs as Potent Degraders across Multiple Cancer Cell Lines. Eur. J. Med. Chem. 2020, 199, 112397. doi.org/10.1016/j.ejmech.2020.112397

6. Zhang, X.; Thummuri, D.; Liu, X.; Hu, W.; Zhang, P.; Khan, S.; Yuan, Y.; Zhou, D.; Zheng, G. Discovery of PROTAC BCL-XL Degraders as Potent Anticancer Agents with Low On-target Platelet Toxicity. Eur. J. Med. Chem. 2020, 192, 112186. doi.org/10.1016/j.ejmech.2020.112186

7. Zhang, X.; Liu, X. L.; Zhou, D.; Zheng, G., Targeting anti-apoptotic BCL-2 family proteins for cancer treatment. Future Med. Chem. 2020, 12, 563-565. (Invited Editorial) doi.org/10.4155/fmc-2020-0004 

8. Zhang, X.; Thummuri, D.; He, Y.; Liu, X.; Zhang, P.; Zhou, D.; Zheng, G., Utilizing PROTAC technology to address the on-target platelet toxicity associated with inhibition of BCL-XL. Chem. Commun. 2019, 55, 14765-14768. doi.org/10.1039/C9CC07217A

9. Khan, S.^#; Zhang, X.^#; Lv, D.^#; Zhang, Q.; He, Y.; Zhang, P.; Liu, X.; Thummuri, D.; Yuan, Y.; Wiegand, J. S.; Pei, J.; Zhang, W.; Sharma, A.; McCurdy, C. R.; Kuruvilla, V. M.; Baran, N.; Ferrando, A. A.; Kim, Y.; Rogojina, A.; Houghton, P. J.; Huang, G.; Hromas, R.; Konopleva, M.; Zheng, G.; Zhou, D. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat. Med. 2019, 25, 1938-1947. doi.org/10.1038/s41591-019-0668-z

10. Moon, S. H.; Zhang, X.; Zheng, G.; Meeker, D. G.; Smeltzer, M. S.; Huang, E., Novel linear lipopeptide paenipeptins with potential for eradicating biofilms and sensitizing Gram-negative bacteria to rifampicin and clarithromycin. J. Med. Chem. 2017, 60, 9630-9640. doi.org/10.1021/acs.jmedchem.7b01064

11. Zhang, X.; Tang, K.; Wang, H.; Liu, Y.; Bao, B.; Fang, Y.; Zhang, X.; Lu, W., Design, synthesis, and biological evaluation of new cathepsin b-sensitive camptothecin nanoparticles equipped with a novel multifuctional linker. Bioconjug. Chem. 2016, 27, 1267-1275. doi.org/10.1021/acs.bioconjchem.6b00099

12. Zhang, X.; Zhang, L.; Liu, Y.; Bao, B.; Zang, Y.; Li, J.; Lu, W., A near-infrared fluorescent probe for rapid detection of hydrogen peroxide in living cells. Tetrahedron 2015, 71, 4842-4845. doi.org/10.1016/j.tet.2015.05.025

13. Zhang, X.; Kong, Y.; Zhang, J.; Su, M.; Zhou, Y.; Zang, Y.; Li, J.; Chen, Y.; Fang, Y.; Zhang, X., Design, synthesis and biological evaluation of colchicine derivatives as novel tubulin and histone deacetylase dual inhibitors. Eur. J. Med. Chem. 2015, 95, 127-135. doi.org/10.1016/j.ejmech.2015.03.035

14. Tang, K.; Huang, J.; Pan, J.*; Zhang, X.*; Lu, W., Design, synthesis and biological evaluation of C(6)-indole celastrol derivatives as potential antitumor agents. RSC Advances 2015, 5, 19620-19623. doi.org/10.1039/C4RA15414B

15. Zhang, X.; Zhang, J.; Su, M.; Zhou, Y.; Chen, Y.; Li, J.; Lu, W., Design, synthesis and biological evaluation of 4′-demethyl-4-deoxypodophyllotoxin derivatives as novel tubulin and histone deacetylase dual inhibitors. RSC Advances 2014, 4, 40444-40448. doi.org/10.1039/C4RA05508J

16. Zhang, X.; Wang, Z.; Huang, Q.; Luo, Y.; Xie, X.; Lu, W., Design, synthesis, and biological evaluation of a new class of MT 2-selective agonists. RSC Advances 2014, 4, 25871-25874. doi.org/10.1039/C4RA03728F

17. Zhang, X.; Zhang, J.; Tong, L.; Luo, Y.; Su, M.; Zang, Y.; Li, J.; Lu, W.; Chen, Y., The discovery of colchicine-SAHA hybrids as a new class of antitumor agents. Biorg. Med. Chem. 2013, 21, 3240-3244. doi.org/10.1016/j.bmc.2013.03.049

18. Zhang, X.; Su, M.; Chen, Y.; Li, J.; Lu, W., The design and synthesis of a new class of RTK/HDAC dual-targeted inhibitors. Molecules 2013, 18, 6491-6503. doi.org/10.3390/molecules18066491

19. Zhang, X.; Bao, B.; Yu, X.; Tong, L.; Luo, Y.; Huang, Q.; Su, M.; Sheng, L.; Li, J.; Zhu, H., The discovery and optimization of novel dual inhibitors of topoisomerase II and histone deacetylase. Biorg. Med. Chem. 2013, 21, 6981-6995. doi.org/10.1016/j.bmc.2013.09.023

20. Zhang, X.; Yuan, W.; Luo, Y.; Huang, Q.; Lu, W., Stereoselective Synthesis of Melatonin Receptor Agonist Ramelteon via Asymmetric Michael Addition. Heterocycles 2012, 85, 73-84. doi: 10.3987/COM-11-12366